skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Generating over 80% of multiple sclerosis (MS) sales in 2025, the US will dictate the overall market dynamics during the entire forecast period. While revenues in all countries are set to expand from 2016 to 2025, those in the US will show the highest growth. Datamonitor Healthcare estimates MS sales in this market will expand from $14.1bn to $26.2bn between 2016 and 2025, growing at an impressive compound annual growth rate of 7.1%. Two key factors will drive the growth of this market: a significant number of pipeline drug launches are expected to create new revenue sources, while continued price inflation in the US will allow established brands to maintain high revenues despite a loss of volume share. Finally, it is important to note that the US has the largest patient pool of all markets forecasted. With over 400,000 diagnosed prevalent MS cases in 2016, its patient population is over three times larger than the second biggest market in this forecast, the UK (see Datamonitor Healthcare’s Epidemiology: Multiple Sclerosis).

 

The substantial growth of the US segment – and of the overall MS market – is highly contingent on the ongoing price increases seen in the country. The rising costs of drugs in the US – both in MS and in other indications – are at the forefront of many political discussions. Datamonitor Healthcare therefore recognizes that if a proposal to cap drug prices is approved, the growth currently forecast for the MS market is likely to be tempered.

 

The US will continue to dictate the trends of the overall multiple sclerosis market

 

Datamonitor Healthcare’s Multiple Sclerosis: Forecast module uses a patient-based forecasting approach to estimate the sales of key marketed and late-phase pipeline drugs across the US, Japan and five major EU markets (France, Germany, Italy, Spain, and the UK) during 2016–25.

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。